Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Regorafenib (Stivarga, BAY73- 4506) Clear all
Active, not recruiting Phase 2 Interventional

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

NCT06087263
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Regorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 3, 2026, 5:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

NCT03563157
View directory record Official record
Conditions
Colorectal Cancer Metastatic, mCRC
Interventions
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

NCT02368886
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment, Regorafenib
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 3, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

NCT04701476
View directory record Official record
Conditions
Colorectal Cancer; Lung Cancer
Interventions
TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Study of Regorafenib and Sildenafil for Advanced Solid Tumors

NCT02466802
View directory record Official record
Conditions
Solid Tumor
Interventions
Regorafenib, Sildenafil Citrate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 3, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ruxolitinib in Colorectal Cancer Patients

NCT02119676
View directory record Official record
Conditions
CRC (Colorectal Cancer)
Interventions
Ruxolitinib, Regorafenib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
57
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

NCT01853046
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 3, 2026, 5:09 PM EDT
Completed No phase listed Observational

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03289273
View directory record Official record
Conditions
Liver Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

NCT01068769
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
regorafenib
Drug
Lead sponsor
Suzanne George, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 3, 2026, 5:09 PM EDT
Active, not recruiting Phase 3 Interventional

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940
View directory record Official record
Conditions
Colorectal Cancer
Interventions
XL092, Atezolizumab, Regorafenib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
45
States / cities
Jonesboro, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

NCT02195011
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
SIR-Spheres, Regorafenib
Device · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 3, 2026, 5:09 PM EDT
Suspended Phase 1 Interventional

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT06454409
View directory record Official record
Conditions
Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Regorafenib, Venetoclax
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

NCT04696055
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 3, 2026, 5:09 PM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

NCT02287025
View directory record Official record
Conditions
Physician Education
Interventions
Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Anaheim, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 3, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

NCT04327700
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraBionic, Regorafenib
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

NCT01973868
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Cetuximab (ERBITUX)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 3, 2026, 5:09 PM EDT
No Longer Available No phase listed Expanded access

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

NCT01538680
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Regorafenib (BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
U.S. locations
62
States / cities
Duarte, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

NCT02096354
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
RRx-001, Regorafenib, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
La Jolla, California • Stanford, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Metastatic Colorectal Cancer

NCT02466009
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib
Drug
Lead sponsor
University of Rochester
Other
Eligibility
70 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Rochester, Minnesota • Rochester, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

NCT02024607
View directory record Official record
Conditions
Advanced Gastrointestinal Cancer
Interventions
BBI608, Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Bevacizumab, Capecitabine, Regorafenib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Fort Myers, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

NCT03042689
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Regorafenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

NCT01774344
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 3, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of Regorafenib in Advanced Pancreatic Cancer Patients

NCT02080260
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
regorafenib
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Albemarle, North Carolina • Charlotte, North Carolina • Concord, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 3, 2026, 5:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

NCT05731947
View directory record Official record
Conditions
Colorectal Cancer, Solid Tumors
Interventions
Revumenib, Chemotherapy
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 3, 2026, 5:09 PM EDT